for you update full-year our business TRACON's fourth call. pipeline update on I will and thank XXXX and quarter results activities. financial afternoon, joining Good an recent and conference and begin with
months Accounting Chief results Officer, Scott year-ended review will XXXX. financial three our Brown, for our the that, and XX, December Following
we will conclude Finally, by taking questions. your
currently primary efforts PDL-X on Our of administration. product in-licensed candidate by inhibitor a are its best-in-class, focused potential our route of recently late-stage subcutaneous virtue Envafolimab, checkpoint
this begin potential sarcoma We study expect a in enrollment to year. second-half pivotal of in in the
our candidate, significant product regard While in we four clinical as we related milestones near-term. stage Envafolimab anticipate the other assets our to also lead
checkpoint At as presented refer Let's the treatment begin which inhibitor Keytruda Undifferentiated irrespective rate study XX with PDL-X Envafolimab, with sarcoma. MFS, patients UPS, Myxofibrosarcoma the we Sarcoma, XXXX, of demonstrating review of XX% a our expression. or for subtype XX the Enva the Pleomorphic in where license SAR ASCO data to of of response or of closely from were achieved related that
study checkpoint multiple agent of trial with in treatment. activity registration-enabling Opdivo Notably, Data sarcoma. we dual inhibitor checkpoint checkpoint indicated than single have ongoing was in subtypes, separate sarcoma demonstrated an from inhibition a planned Yervoy are that while in effective a with Opdivo or more and sarcoma inhibitors unaware immune
of a and in X initially opinion our unmet a MFS have payers. in frontline sarcoma develop refractory subtypes patients with we angiosarcoma. satisfy and These a completed study TAPPAS be that is patients, to and Phase relationships know, Trial many As and our key potentially indicated registration-enabling strategy as in sarcomas high medical UPS would need opinion leaders Therefore, physicians, of close valuable in to the of result checkpoint successful key inhibitor this leaders you patients. maintain
was the new our experience we in sites in study to study a possess sarcoma. States TAPPAS in Given European conducted and XX countries, the rapidly unique agent and multiple at capacity United
FDA, combination a Subject input will marketed is the initiate approximately include second by that BMS. inhibitor targeting to of the cohort who from XX who single pivotal with we of a second a cohort expect agent to that will will checkpoint Yervoy, potential approximately and Enva, receive XX Enva receptor one patients in receive patients CTLA-X trial
will each cohorts. each the expect endpoint in the and objective response be XX% that We the of rate, rate of expect primary two in target cohorts objective to response a
these Votrient, rate. which approved patients, following objective prior treatment sarcoma for is X% a response the has chemotherapy, of
rate patients higher care. of a So, population be the meaningful advance in of would response significantly cancer a demonstration a this in standard of
is the in as design provides as patients agent, the is was risk with dual-arm in combination design to Yervoy single with treatment trial approval Therefore, the and trial basis the for our design of agent in required sarcoma as that showed a robust by compared could rate response trial mitigation be we the Enva well combination believe Oncology case the design the Lancet of for Yervoy, FDA Alliance in accelerated for activity. This to similar combining increase and published funded trial single Opdivo. Opdivo This XXXX. by in NCI completed that
of and XXXX, having U.S. receive FDA trial. XXXX: trial in file will potential we drug In milestones potential corporate expect a orphan an clinical a regarding initiate in our with IND of if assuming designation cross-referencing and in the Enva design, clinical data, the the for XXXX, commercial response positive the following that XXXX. interim permit accelerated sarcoma, BLA approval, in IND mid meet approved, the having early near-term, for the an deliver partner, the assessment to determination in a in launch submitting assessment dosing estimate We pivotal final in open response
$XXX positive refractory sarcoma UPS a part to trial nearly estimate U.S. therapy or inhibitor of This as generate multiple parity agent the biomarker-directed checkpoint and in trial and biomarker single could from approved in patient the as that UPS expand in assuming include another and or of be with initiate initial pricing to the soft provided MFS, on Additionally, trial enrollment could initial population. a refractory intend will combined MFS. for data MFS Yervoy a revenue Enva trial based analyses in of Keytruda Opdivo. we We target million conducted for randomized the tissue UPS cancer refractory subtypes to
revenues is setting. other course, if expanded could first-line Of subtypes sarcoma increase the into treatment in
given format antibody is subcutaneously. the Let's Cablivi. asset company from that Enva promising benefits of Ablynx, now antibody inhibitor in discuss virtue single-domain Enva potential markets pioneered that by detail. a a Sanofi the fact This further that best-in-class is single-domain by it was the PDL-X
inhibitors, the injection, is compared more convenience. administration convenient due As following subcutaneous the potential by enables formulation compared The approved First, for to which patients. better has greater to checkpoint Enva patient to faster much an a and for potentially infusion compliance advantages: intravenous self result, administration patient
significant administration, fluctuations class subcutaneous achieved of without can the improve may due relatively stable which nature safety. to of Second, be drug concentrations
into penetrate Third, a smaller molecule tumors could improve to efficacy. better
studies, China. In China, Phase trials tract U.S., than administered eight ongoing mean in of cancer in ongoing U.S. studied trials. weeks. every half-life levels including patients high to patients X dosing and biliary increased suggest dose-dependent has support PK XXX allowed trial hours. two for and proportionally Enva the a in a in frequent and cancer four-week the studies, a with currently That trials exposure Japan, would China, more half-life dose was escalation in analyses randomized in to for Enva a and X approximately schedule, pivotal serum these is less single-arm at dose in XXX Phase Phase escalation X MFS Japanese least been sustained dosing being clinical and
the and Data Phase other inhibitors, lung overall increases, of by renal with trial impressed XX the were ASCO cancer consistent drug including responses, X Japanese events. PDL-X low-grade profile with were from most clinical including function adverse We presented presented had XXXX. were Data in responses, and activity responses. one cancer. of common were that biliary confirmed the Phase had eval safety and Two MSI nine trials. ASCO had with Phase at Chinese High and The one cell anemia partial confirmed trial unconfirmed prostate at patients Three low-grade of Phase the carcinoma at had being partial from X cancer X presented XXXX. U.S. of and trial patient, eval partial liver of patient. of test testing trial patients XX Data XXXX. Two partial ESMO the the responses, tract confirmed X patients from two patients patients
partner data XD our an Notably, patients for BLA trial, from ongoing Medicines China in intends and based a file on in with pivotal Enva XXXX, tumors. to MSI-high
that for must inhibitor filing approval response Importantly, to the principle products predicated the for MSI-high is in the response the approved China required PD-X objective similar U.S. objective be in patients. rate for cancer on the
America. is directly develop TRACON's and agreement capital Enva upfront The as expeditiously trial Instead Medicines clinical paying a be Alphamab and used clinical the to license fee, possible. Enva traditional development to commercialize as agreement of with will and in in collaboration advance XD a North of sarcoma
the trials filings As signed development in with to capability I-Mab two will and the our clinical regulatory other again sarcoma. our with in leveraged TRACON has clinical agreements bear costs we U.S., all lead XXXX, in independent of CRO and
be Enva outside pre-negotiated use. sarcoma. well Medicines North America in all clinical right indications all territories supplying will of other prices America, for and responsible develop as to TRACON retains XD within than Enva Alphamab Alphamab to the at as and North for for commercial
sales, and commercialization of will America present option we leads sarcoma was or North XD royalties royalties in [cheered] in on which XX% than do from lead and and or Medicines an on in in teens and the that [elect XD a] sarcoma cheered a sales receive approved case the we net from mid-double non-open mid-double Enva book owe in and will indication Medicines royalty Medicines sales, to sales other XD the is Alphamab sarcoma commercialization, Enva approved if digits. commercialization, on [ph] XD TRACON UNLESS, America, to sarcoma, co-market not in North with receive ranging to [ph] subsequently first supposed which digits. from we and have to revenue. will If market, in includes a indication sarcoma sales teens booking ranging
of the Provided, and consent, our without sarcoma America have program value TRACON, for Medicines good of in reacquire trial XD with to sale pivotal entire will the the in the Enva of to third-party. the right compensation completion sale connection a in that and to however, not the product in will for at occur North Alphamab prior a negotiate time. given we the the faith
now with our other clinical stage antibody assets turn beginning Let's our and four to DE-XXX.
analyzing most patients Phase the to Santen, and DE-XXX recent trial base net to royalty of of sites X, earnings DE-XXX, that low this data milestones, clinical of from licensee, compares agent doses acuity including XX significant of X endpoint the with first-half the study. are Our AVANTE in randomized the regulatory commercialization two line developmental, grew enrollment in single-digit the of X currently including the million three-arm teen call Lucentis six with and during The Santen data, AVANTE in mid-XXXX expected following and different at $XXX with high visual TRACON February they're sales. completed study dosing corrected rights breast treatment financial months single year. Lucentis. retains on in a treatment remaining combined U.S. top global with Phase announced success primary their On
to mesothelioma patients small repair NCI of or that to excision is are Phase We third lung resistance basic now certain The TRCXXX, or X to focused pathway chemotherapeutics. is non-small critical supporting four cancer. on which X will stage the Phase asset, molecule turn that reverse is with another cell DNA intended trials our inhibitor
treated in from correlates completed clinical continue that ongoing a or expression specimens tumor our trials academic the from TRCXXX trial, addition, profile tumor glioblastoma biomarkers with and patients with our in response. gene X In Phase and of laboratories protein to in identifying evaluate specimens goal patients
clinical multiple expect at clinical TRCXXX We presented trials ASCO from be XXXX. will data
lower-than-expected fourth treatment a or with a in In asset now resistance of we for Erleada. clinical announced mutation. metastatic to with basis response with with move X/X prostate with receptor more to TRCXXX Xtandi point mutation, patients one three that the We that FXXXL that than cancer, applied to Erleada. enrollment available resistance that mutation, Xtandi on patients data another indicated castrate another the patients indicate that who with Phase developed studying and we're trial XXXX, into those undisclosed cancer, of XX FXXXL completed we stage cohorts androgen in those resistant or of of we will or a initial prostate time, those mutation, an At rate in therapy and lower-than-expected-prevalence to
Janssen upfront or U.S. in to TRCXXX X in to a with of will which expect XXXX, of assets. million We often payment not Phase China. single-digit in that the independently on opt-in, deliver are trigger a Janssen to during enrolled success-based proof-of-concept In all Janssen case, milestones $XX low a in which receive If abroad, to sales. and partner TRACON reacquire TRACON royalty exercise the first-half currently million $XXX.X right kind period, the including entitled patients data does to XX-day a is on and up advance
Our Phase with fifth supplied X checkpoint agent in CDXX inhibitor been dose a being is by TJXXXX, studied clinical antibody single a study has a and combination as escalation tri-centric, marketed asset which stage Roche. in the
through out of payments this to presenting TRACON responsible the In X I-Mab anticipate development collaboration non-royalty Biopharma common I-Mab the third-party. in and for to of to the TJXXXX escalating and is and And clinical escalation U.S. second-half TRACON We TJXXXX in them, top license likes regulatory if is we and royalty TJXXXX line Europe. from are dose trial in a the agreement in receive collaboration, and our entitled of data portions developing with with first completing Phase XXXX.
especially is agreement up or in the treatment. direct bispecific collaboration those multi-product with antibodies potential exciting in hot, therapeutic tumor I-Mab a tumors for the develop cancer Our words, make America. other five to in have antibodies, to North We that the most cold to of second T-cells microenvironment, approaches to bispecific believe I-Mab's to that,
a seven to At access a Further, we as this innovation. a source view I-Mab viable potential continued multi-product time, preclinical antibodies. disclosed has they're pipeline bispecific of advancing
the and U.S. and collaboration, share For commercialization. antibodies more of I-Mab will two cost profits advanced commercialization and cost the U.S., the any U.S. clinical from subject stages commercialization in development will becomes share and development lead to trials. and in equally by TRACON for companies bispecific early of that the the will the also clinical TRACON phase
is prior include the to to Another to pivotal element to that all each our the The of will disagreement this of from I-Mab TRACON's bispecific in collaboration any worth point opt-in territories noting Greater antibody becomes license China. the to development. phase Exercising right advancing study. payments at of rights escalate conclusion option of the outside subject reflect expand
For of prior example, an to studies. $XX due enabling exercise opt-in option to payment is million IND this TRACON
have new XXXX. corporate development to the first file U.S. activities, an expect We further continue goal I-Mab or to the respect best-in-class, bispecific for XXXX; or best-in-class from our first-in remains four in clinical asset, in partnerships business case, without stage each IND potential establish we in or antibody scope With to to Notably, of fast-forward payment. class, of licenses the around first assets. since an upfront existing completed enlarge partnerships potential
to assets potential continue this We for using evaluate and our profit model. risk, share novel time cost, at license
From decreased only program. our ATM as a clinical expense currently our year. a capital result we of XXXX, and the are we decreased of noteworthy cash one financial of is From raised expenses it in have that for significant earlier for perspective, point use and improved view, trial expenses creating runway this a
in are of second-half is of the funded enrollment development only second-half As to completed. begin the year, TRCXXX NCI, expenses increase funded clinical DE-XXX Santen, been is development efficiencies product and to burn but the expected this expected TRCXXX development Enva by the given marginally has platform. by our
as in compliance equity of increased also result February achieved requirements utilization the with ATM. We established the shareholder capital the listing NASDAQ markets of a and
plant multiple are Our through of creating operations currently the sufficient capital expected and potential first fund be to bad business development XXXX, our political quarter resources into to and milestones.
our the the request which Furthermore, our from we through our up under million during runway XX-month sale, of XXXX. cash purchase the to time facility would $XX can common XQ with our over market into based cash agreement estimate if is at fully utilized, they're period extend potentially price, this further of price difficulty] each committed Capital, the we on extend time-to-time Aspire at to stock [technical runway the
to and through Importantly, be non-dilutive from our partnerships success-based Santen, with financial extended Janssen, capital could milestones runway further I-Mab.
provide financials. Scott time, At will our this an update on
